title: Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium.
abstract: Oncolytic viruses are currently in clinical trials for a variety of tumors, including high grade gliomas. A characteristic feature of high grade gliomas is their high vascularity and treatment approaches targeting tumor endothelium are under investigation, including bevacizumab. The aim of this study was to improve oncolytic viral therapy by combining it with ionizing radiation and to radiosensitize tumor vasculature through a viral encoded anti-angiogenic payload. Here, we show how vaccinia virus-mediated expression of a single-chain antibody targeting VEGF resulted in radiosensitization of the tumor-associated vasculature. Cell culture experiments demonstrated that purified vaccinia virus encoded antibody targeting VEGF reversed VEGF-induced radioresistance specifically in endothelial cells but not tumor cells. In a subcutaneous model of U-87 glioma, systemically administered oncolytic vaccinia virus expressing anti-VEGF antibody (GLV-1h164) in combination with fractionated irradiation resulted in enhanced tumor growth inhibition when compared to nonanti-VEGF expressing oncolytic virus (GLV-1h68) and irradiation. Irradiation of tumor xenografts resulted in an increase in VACV replication of both GLV-1h68 and GLV-1h164. However, GLV-1h164 in combination with irradiation resulted in a drastic decrease in intratumoral VEGF levels and tumor vessel numbers in comparison to GLV-1h68 and irradiation. These findings demonstrate the incorporation of an oncolytic virus expressing an anti-VEGF antibody (GLV-1h164) into a fractionated radiation scheme to target tumor cells by enhanced VACV replication in irradiated tumors as well as to radiosensitize tumor endothelium which results in enhanced efficacy of combination therapy of human glioma xenografts.
authors.affiliation: Department of Biochemistry, Rudolph Virchow Center for Experimental Biomedicine and Institute for Molecular Infection Biology, University of Würzburg, D-97074, Würzburg, Germany; Genelux Corporation, San Diego Science Center, San Diego, CA.
authors.forename: Lisa
authors.initials: L
authors.lastname: Buckel
authors.forename: Sunil J
authors.initials: SJ
authors.lastname: Advani
authors.forename: Alexa
authors.initials: A
authors.lastname: Frentzen
authors.forename: Qian
authors.initials: Q
authors.lastname: Zhang
authors.forename: Yong A
authors.initials: YA
authors.lastname: Yu
authors.forename: Nanhai G
authors.initials: NG
authors.lastname: Chen
authors.forename: Klaas
authors.initials: K
authors.lastname: Ehrig
authors.forename: Jochen
authors.initials: J
authors.lastname: Stritzker
authors.forename: Arno J
authors.initials: AJ
authors.lastname: Mundt
authors.forename: Aladar A
authors.initials: AA
authors.lastname: Szalay
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D004730:Endothelium, Vascular / Q000528:radiation effects*; D005910:Glioma / Q000098:blood supply / Q000628:therapy*; D006801:Humans; D008297:Male; D051379:Mice; D050130:Oncolytic Virotherapy / Q000379:methods*; D011836:Radiation Tolerance; D014616:Vaccinia virus / Q000235:genetics*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: D042461:Vascular Endothelial Growth Factor A
keywords: VEGF; combination therapy; glioma; radiosensitization; vaccinia virus